Backbase unveils Intelligence Fabric to unlock AI-productivity gains for banks 25-09-2024, 15:29

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

VCI Global Targets US$200 Million Revenue with 100 MW of Solar Photovoltaic Projects in Southeast Asia and Europe 13-12-2024, 20:33